Diagnostic value of blood exosomal RNA in several common tumors: a multicenter clinical study
|
注册号: Registration number: |
ChiCTR2400083590 |
|
最近更新日期: Date of Last Refreshed on: |
2024-04-29 09:53:36 |
|
注册时间: Date of Registration: |
2024-04-29 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
血液外泌体RNA在多种常见肿瘤中的诊断价值:一项多中心临床研究 |
|
Public title: |
Diagnostic value of blood exosomal RNA in several common tumors: a multicenter clinical study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
血液外泌体RNA在多种常见肿瘤中的诊断价值:一项多中心临床研究 |
|
Scientific title: |
Diagnostic value of blood exosomal RNA in several common tumors: a multicenter clinical study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王祖恒 |
研究负责人: |
王富博 |
|
Applicant: |
Zuheng Wang |
Study leader: |
Fubo Wang |
|
申请注册联系人电话: Applicant telephone: |
+86 188 1153 0070 |
研究负责人电话: Study leader's telephone: |
+86 135 8555 1316 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
w2630064912@163.com |
研究负责人电子邮件: Study leader's E-mail: |
wangbofengye@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广西南宁市青秀区双拥路22号 |
研究负责人通讯地址: |
广西南宁市青秀区双拥路22号 |
|
Applicant address: |
22 Shuangyong Road, Nanning, Guangxi, China |
Study leader's address: |
22 Shuangyong Road, Nanning, Guangxi, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
广西医科大学 |
||
|
Applicant's institution: |
Guangxi Medical University |
||
|
研究负责人所在单位: |
广西医科大学 |
||
|
Affiliation of the Leader: |
Guangxi Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024年KY0004号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
广西医科大学医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Guangxi Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-01-23 00:00:00 |
||
|
伦理委员会联系人: |
杨小钵 |
||
|
Contact Name of the ethic committee: |
Xiaobo Yang |
||
|
伦理委员会联系地址: |
广西南宁市青秀区双拥路22号 |
||
|
Contact Address of the ethic committee: |
22 Shuangyong Road, Nanning, Guangxi, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 132 2272 8173 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
广西医科大学 |
||||||||||||||||||||||
|
Primary sponsor: |
Guangxi Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广西南宁市青秀区双拥路22号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
22 Shuangyong Road, Nanning, Guangxi, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
self-financing |
||||||||||||||||||||||
|
Target disease: |
several common tumors |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
诊断试验 |
||||||||||||||||||||||
|
Study type: |
Diagnostic test |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
诊断试验诊断准确性 |
||||||||||||||||||||||
|
Study design: |
Diagnostic test for accuracy |
||||||||||||||||||||||
|
研究目的: |
基于血液外泌体RNA建立多种恶性肿瘤诊断新方法 |
||||||||||||||||||||||
|
Objectives of Study: |
Establishment of a new diagnostic method for multiple malignant tumours based on blood exosomal RNAs. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
无 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
Not applicable. |
||||||||||||||||||||||
|
纳入标准: |
病例组: 1.年龄≥18周岁,性别不限; 2.经手术病理或活检病理确诊为以下肿瘤中一种者:乳腺癌、肝细胞癌、胰腺腺癌、结直肠腺癌,卵巢癌、肾透明细胞癌、前列腺腺癌、肺腺癌。 3.首诊:没有抗肿瘤史,包括抗肿瘤药物治疗、手术治疗、内分泌治疗、放化疗等;没有既往肿瘤史。 健康人组: 1.年龄≥18周岁,性别不限; 2.经影像学检查等确认,无器官肿瘤者 |
||||||||||||||||||||||
|
Inclusion criteria |
Case group: 1. Age ≥ 18 years old, gender not limited. 2. Diagnosed with one of the following tumours by surgical pathology or biopsy pathology: breast cancer, hepatocellular carcinoma, pancreatic adenocarcinoma, colorectal adenocarcinoma, ovarian cancer, renal clear cell carcinoma, prostate adenocarcinoma, lung adenocarcinoma. 3. First diagnosis: no history of anti-tumour, including anti-tumour drug treatment, surgical treatment, endocrine treatment, radiotherapy, etc.; no previous history of tumour. Healthy people group: 1. Age ≥ 18 years old, gender not limited. 2. Those who have no organ tumour as confirmed by imaging examination, etc. |
||||||||||||||||||||||
|
排除标准: |
1.除上述肿瘤外,其他器官发生肿瘤者; 2.合并2种或以上上述肿瘤者; 3.既往抗肿瘤治疗者; 4.合并认知功能障碍者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Those who have tumours in organs other than those mentioned above. 2. Those with a combination of 2 or more of the above tumours. 3. Those with previous anti-tumour treatment. 4. People with combined cognitive dysfunction. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-04-20 00:00:00至 To 2027-04-20 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-04-30 00:00:00 至 To 2027-04-20 00:00:00 |
|
诊断试验: Diagnostic Tests: |
|
||||||||||||||||||||||||||||
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
不适用 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Not applicable. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
Not applicable. |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
基于合理的要求联系项目负责人 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Contact the study leader upon reasonable request. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |